Circuitries involved in the control of energy homeostasis and the hypothalamic-pituitary-adrenal axis activity

Treatments in Endocrinology

Volumn 3, Issue 5, 2004, Pages 269-277

  Richard, Denis ^a,b   Baraboi, Dana ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN; AMPHETAMINE DERIVATIVE; CANNABINOID; COCAINE; CORTICOTROPIN RELEASING FACTOR; MELANIN CONCENTRATING HORMONE; MELANOCORTIN; NEUROPEPTIDE; NEUROPEPTIDE Y; OREXIN; PROTIRELIN; UROCORTIN;

BODY WEIGHT; ENERGY BALANCE; ENERGY EXPENDITURE; FOOD INTAKE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; THERMOGENESIS;

ANIMALS; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM;

EID: 4644299524     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403050-00001     Document Type: Review

References (163)

1. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-43
2. Despres JP. Drug treatment for obesity: we need more studies in men at higher risk of coronary events. BMJ 2001; 322: 1379-80
3. Strack AM, Bradbury MJ, Dallman MF. Corticosterone decreases nonshivering thermogenesis and increases lipid storage in brown adipose tissue. Am J Physiol Regul Integr Comp Physiol 1995; 37: R183-91
4. Galpin KS, Henderson RG, James WPT, et al. GDP binding to brown-adipose-tissue mitochondria of mice treated chronically with corticosterone. Biochem J 1983; 214: 265-8
5. Arvaniti K, Ricquier D, Champigny O, et al. Leptin and corticosterone have opposite effects on food intake and the expression of UCP1 mRNA in brown adipose tissue of lep(ob)/lep(ob) mice. Endocrinology 1998; 139: 4000-4
6. Strack AM, Sebastian RJ, Schwanz MW, et al. Glucocorticoids and insulin: reciprocal signals for energy balance. Am J Physiol Regul Integr Comp Physiol 1995; 37: R142-9
7. Pasquali R, Vicennati V. The abdominal obesity phenotype and insulin resistance are associated with abnormalities of the hypothalamic-pituitary- adrenal axis in humans. Horm Metab Res 2000; 32: 521-5
8. Ueland T, Kristo C, Godang K, et al. Interleukin-1 receptor antagonist is associated with fat distribution in endogenous Cushing's syndrome: a longitudinal study. J Clin Endocrinol Metab 2003; 88: 1492-6
9. Timofeeva E, Richard D. Functional activation of CRH neurons and expression of the genes encoding CRH and its receptors in food-deprived lean (Fa/?.) and obese (fa/fa) Zucker rats. Neuroendocrinology 1997; 66: 327-40
10. Alarrayed F, Hartman AD, Porter JR. Is there a role for the adrenals in the development of hypercholesterolemia in Zucker fatty rats. Am J Physiol 1992; 263: E287-95
11. Guillaume-Gentil C, Rohner-Jeanrenaud F, Abramo F, et al. Abnormal regulation of the hypothalamo-pituitary-adrenal axis in the genetically obese fa/fa rat. Endocrinology 1990; 126: 1873-9
12. Tsai HJ, Romsos DR. Glucocorticoid and mineralocorticoid receptor-binding characteristics in obese (ob/ob) mice. Am J Physiol 1991; 261: E495-9
13. McGinnis R, Walker J, Margules D, et al. Dysregulation of the hypothalamus-pituitary-adrenal axis in male and female, genetically obese (ob/ob) mice. J Neuroendocrinol 1992; 4: 765-71
14. White BD, Corll CB, Porter JR. The metabolic clearance rate of corticosterone in lean and obese male Zucker rats. Metabolism 1989; 38: 530-6
15. Vettor R, Vicennati V, Gambineri A, et al. Leptin and the hypothalamic-pituitary-adrenal axis activity in women with different obesity phenotypes. Int J Obes 1997; 21: 708-11
16. Bjorntorp P, Rosmond R. Obesity and cortisol. Nutrition 2000; 16: 924-36
17. Schwartz MW, Woods SC, Porte Jr D, et al. Central nervous system control of food intake. Nature 2000; 404: 661-71
18. Elmquist JK. Anatomic basis of leptin action in the hypothalamus. Front Horm Res 2000; 26: 21-41
19. Cone RD. The central melanocortin system and energy homeostasis. Trends Endocrinol Metab 1999; 10: 211-6
20. Richard D. The role of CRF in the regulation of energy balance. Curr Opin Endocrinol Diabetes 1999; 6: 10-8
21. Sleeman MW, Anderson KD, Lambert PD, et al. The ciliary neurotrophic factor and its receptor, CNTFR alpha. Pharm Acta Helv 2000; 74: 265-72
22. Williams G, Harrold JA, Cutler DJ. The hypothalamus and the regulation of energy homeostasis: lifting the lid on a black box. Proc Nutr Soc 2000; 59: 385-96
23. Woods SC, Schwartz MW, Baskin DG, et al. Food intake and the regulation of body weight. Annu Rev Psychol 2000; 51: 255-77
24. Stanley SA, Small CJ, Murphy KG, et al. Actions of cocaine- and amphetamine-regulated transcript (CART) peptide on regulation of appetite and hypothalamo-pituitary axes in vitro and in vivo in male rats. Brain Res 2001; 893: 186-94
25. Vrang N, Larsen PJ, Kristensen P, et al. Central administration of cocaine-amphetamine-regulated transcript activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 2000; 141: 794-801
26. Hanson ES, Dallman MF. Neuropeptide y (NPY) may integrate responses of hypothalamic feeding systems and the hypothalamo-pituitary-adrenal axis. J Neuroendocrinol 1995; 7: 273-9
27. Kuru M, Ueta Y, Serino R, et al. Centrally administered orexin/hypocretin activates HPA axis in rats. Neuroreport 2000; 11: 1977-80
28. Bluet-Pajot MT, Presse F, Vokö Z, et al. Neuropeptide-E-I antagonizes the action of melanin-concentrating hormone on stress-induced release of adrenocorticotropin in the rat. J Neuroendocrinol 1995; 7: 297-303
29. Johnson KM, Dewey WL, Ritter KS, et al. Cannabinoid effects on plasma corticosterone and uptake of 3H-corticosterone by mouse brain. Eur J Pharmacol 1978; 47: 303-10
30. Weidenfeld J, Feldman S, Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 1994; 59: 110-2
31. Papadopoulos AD, Wardlaw SL. Endogenous alpha-MSH modulates the hypothalamic-pituitary-adrenal response to the cytokine interleukin-1beta. J Neuroendocrinol 1999; 11: 315-9
32. Mountjoy KG, Wong J. Obesity, diabetes and functions for proopiomelanocortin-derived peptides. Mol Cell Endocrinol 1997; 128: 171-7
33. Wikberg JES. Melanocortin receptors: new opportunities in drug discovery. Expert Opin Ther Patents 2001; 11: 61-76
34. Chen AS, Marsh DJ, Trumbauer ME, et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000; 26: 97-102
35. Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88: 131-41
36. Lu D, Willard D, Patel IR, et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994; 371: 799-802
37. Hagan MM, Benoit SC, Rushing PA, et al. Immediate and prolonged patterns of agouti-related peptide-(83-132)-induced c-Fos activation in hypothalamic and extrahypothalamic sites. Endocrinology 2001; 142: 1050-6
38. Hahn TM, Breininger JF, Baskin DG, et al. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998; 1: 271-2
39. Shutter JR, Graham M, Kinsey AC, et al. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev 1997; 11: 593-602
40. Mizuno TM, Mobbs CV. Hypothalamic agouti-related protein messenger ribonucleic acid is inhibited by leptin and stimulated by fasting. Endocrinology 1999; 140: 814-7
41. DiMarzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-5
42. Bisogno T, Berrendero F, Ambrosino G, et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 1999; 256: 377-80
43. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635-64
44. Zuardi AW, Teixeira NA, Karniol IC. Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch Int Pharmacodyn Ther 1984; 269: 12-9
45. Manzanares J, Corchero J, Fuentes JA. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res 1999; 839: 173-9
46. Wenger T, Jamali KA, Juaneda C, et al. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem Biophys Res Commun 1997; 237: 724-8
47. Hao S, Avraham Y, Mechoulam R, et al. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 2000; 392: 147-56
48. Di S, Malcher-Lopes R, Halmos KC, et al. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 2003; 23: 4850-7
49. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-85
50. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998; 95: 322-7
51. Chemelli RM, Wille JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437-51
52. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015
53. Cutler DJ, Morris R, Sheridhar V, et al. Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord. Peptides 1999; 20: 1455-70
54. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001; 435: 6-25
55. Sweet DC, Levine AS, Billington CJ, et al. Feeding response to central orexins. Brain Res 1999; 821: 535-8
56. Timofeeva E, Picard F, Duclos M, et al. Neuronal activation and corticotropin-releasing hormone expression in the brain of obese (fa/fa) and lean (fa/?.) Zucker rats in response to refeeding. Eur J Neurosci 2002; 15: 1013-29
57. Cai XJ, Widdowson PS, Harrold J, et al. Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes 1999; 48: 2132-7
58. Cai XJ, Denis R, Vernon RG, et al. Food restriction selectively increases hypothalamic orexin-B levels in lactating rats. Regul Pept 2001; 97: 163-8
59. Yamanaka A, Sakurai T, Katsumoto T, et al. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 1999; 849: 248-52
60. Sakurai T. Roles of orexins in regulation of feeding and wakefulness. Neuroreport 2002; 13: 987-95
61. Sakurai T. Orexin: a link between energy homeostasis and adaptive behaviour. Curr Opin Clin Nutr Metab Care 2003; 6: 353-60
62. Vale W, Spiess J, Rivier C, et al. Characterization of a 41 -residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981; 213: 1394-7
63. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995; 378: 287-92
64. Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A 2001; 98: 2843-8
65. Hsu SY, Hsueh AJW. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 2001; 7: 605-11
66. Lewis K, Li C, Perrin MH, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A 2001; 98: 7570-5
67. Turnbull AV, Rivier C. Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides. Proc Soc Exp Biol Med 1997; 215: 1-10
68. Brown MR, Fisher LA. Regulation of the autonomic nervous system by corticotropin-releasing factor. In: De Souza EB, Nemeroff CB, editors. Corticotropin-releasing factor: basic and clinical studies of a neuropeptide. Boca Raton (FL): CRC, 1990: 291-8
69. Heinrichs SC, Tache Y. Therapeutic potential of CRF receptor antagonists: a gut-brain perspective. Expert Opin Investig Drugs 2001; 10: 647-59
70. Koob GF, Cole BJ, Swerdlow NR, et al. Stress, performance, and arousal: focus on CRF. NIDA Res Monogr 1990; 97: 163-76
71. Krysiak R, Obuchowicz E, Herman ZS. Role of corticotropin-releasing factor (CRF) in anxiety. Pol J Pharmacol 2000; 52: 15-25
72. Spina M, Merlo-Pich E, Chan RKW, et al. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996; 273: 1561-4
73. Million M, Saunders P, Rivier J, et al. Compound 338-86-15, a novel peptide CRF-R2 antagonist, selectively blocks CRF and stress-induced delayed gastric emptying in rats [abstract]. Soc Neurosci Abstr 2001; 27: 839.17
74. Krahn DD, Gosnell BA, Levine AS, et al. Behavioral effects of corticotropin-releasing factor: localization and characterization of central effects. Brain Res 1988; 443: 63-9
75. Currie PJ, Coscina DV, Bishop C, et al. Hypothalamic paraventricular nucleus injections of urocortin alter food intake and respiratory quotient. Brain Res 2001; 916: 222-8
76. Wang C, Mullet MA, Glass MJ, et al. Feeding inhibition by urocortin in the rat hypothalamic paraventricular nucleus. Am J Physiol Regul Integr Comp Physiol 2001: 280: R473-80
77. Bakshi VP, Newman HC, Weinberg LE, et al. Urocortin infusion into lateral septum increases grooming and decreases ingestive behaviors [abstract]. Abstr Soc Neurosci 2001; 27: 414.14
78. Kelly AB, Watts AG. The region of the pontine parabrachial nucleus is a major target of dehydration-sensitive CRH neurons in the rat lateral hypothalamic area. J Comp Neurol 1998; 394: 48-63
79. Watts AG, Sanchez-Watts G, Kelly AB. Distinct patterns of neuropeptide gene expression in the lateral hypothalamic area and arcuate nucleus are associated with dehydration-induced anorexia. J Neurosci 1999; 19: 6111-21
80. Egawa M, Yoshimatsu H, Bray GA. Preoptic area injection of corticotropin-releasing hormone stimulates sympathetic activity. Am J Physiol 1990; 259: R799-806
81. Hashimoto K, Makino S, Asaba K, et al. Physiological roles of corticotropin-releasing hormone receptor type 2. Endocr J 2001 ; 48: 1-9
82. Katner JS, Li DL, Grigoriadis DE, et al. Urocortin modulates food consumption and body weight via CRF2a receptor. Abstr Soc Neurosci 2001; 27: 477.10
83. Cullen MJ, Ling N, Foster AC, et al. Urocortin, corticotropin releasing factor-2 receptors and energy balance. Endocrinology 2001; 142: 992-9
84. Contarino A, Heinrichs SC, Gold LH. Understanding corticotropin releasing factor neurobiology: contributions from mutant mice. Neuropeptides 1999; 33: 1-12
85. Richard D, Rivest R, Naimi N, et al. Expression of corticotropin- releasing factor and its receptors in the brain of lean and obese Zucker rats. Endocrinology 1996; 137: 4786-95
86. Makino S, Nishiyama M, Asaba K, et al. Altered expression of type 2 CRH receptor mRNA in the VMH by glucocorticoids and starvation. Am J Physiol Regul Integr Comp Physiol 1998; 44: R1138-45
87. Schwartz MW, Figlewicz DP, Baskin DG, et al. Insulin in the brain: a hormonal regulator of energy balance. Endocr Rev 1992; 13: 387-414
88. Schwartz MW. Biomedicine: staying slim with insulin in mind. Science 2000; 289: 2066-7
89. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62: 413-37
90. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70
91. Dallman MF, Akana SF, Strack AM, et al. The neural network that regulates energy balance is responsive to glucocorticoids and insulin and also regulates HPA axis responsivity at a site proximal to CRF neurons. Ann N Y Acad Sci 1995; 771: 730-42
92. Cabanac M, Richard D. The nature of the ponderostat: Hervey's hypothesis revived. Appetite 1996; 26: 45-54
93. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-13
94. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from the stomach. Nature 1999; 402: 656-60
95. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-8
96. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-9
97. Banks WA. Leptin transport across the blood-brain barrier: implications for the cause and treatment of obesity. Curr Pharm Des 2001; 7: 125-33
98. Banks WA, Kastin AJ, Huang WT, et al. Leptin enters the brain by a saturable system independent of insulin. Peptides 1996; 17: 305-11
99. Wilkinson M, Morash B, Ur E. The brain is a source of leptin. Front Horm Res 2000; 26: 106-25
100. Schwartz MW, Baskin DG, Bukowski TR, et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996; 45: 531-5
101. Kristensen P, Judge ME, Thim L, et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998; 393: 72-6
102. Thornton JE, Cheung CC, Clifton DK, et al. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 1997; 138: 5063-6
103. Arvaniti K, Huang OL, Richard D. Effects of leptin and corticosterone on the expression of corticotropin-releasing hormone, agouti-related protein, and proopiomelanocortin in the brain of ob/ob mouse. Neuroendocrinology 2001; 73: 227-36
104. El-Haschimi K, Pierroz DD, Hileman SM, et al. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000; 105: 1827-32
105. Bates SH, Stearns WH, Dundon TA, et al. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 2003; 421: 856-9
106. Huang Q, Rivest R, Richard D. Effects of leptin on corticotropin- releasing factor (CRF) synthesis and CRF neuron activation in the paraventricular hypothalamic nucleus of obese (ob/ob) mice. Endocrinology 1998; 139: 1524-32
107. Heiman ML, Ahima RS, Craft LS, et al. Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. Endocrinology 1997; 138: 3859-63
108. Giovambattista A, Chisari AN, Gaillard RC, et al. Food intake-induced leptin secretion modulates hypothalamo-pituitary-adrenal axis response and hypothalamic Ob-Rb expression to insulin administration. Neuroendocrinology 2000; 72: 341-9
109. Lopez M, Seoane L, Garcia MC, et al. Leptin regulation of prepro-orexin and orexin receptor mRNA levels in the hypothalamus. Biochem Biophys Res Commun 2000; 269: 41-5
110. Friedman MI, Ramirez I. Food intake in diabetic rats: relationship to metabolic effects of insulin treatment. Physiol Behav 1994; 56: 373-8
111. Schwartz MW, Sipols AJ, Marks JL, et al. Inhibition of hypothalamic neuropeptide-Y gene expression by insulin. Endocrinology 1992; 130: 3608-16
112. Kotz CM, Briggs JE, Pomonis JD, et al. Neural site of leptin influence on neuropeptide Y signaling pathways altering feeding and uncoupling protein. Am J Physiol Regul Integr Comp Physiol 1998; 44: R478-84
113. Havel PJ, Hahn TM, Sindelar DK, et al. Effects of streptozotocin-induced diabetes and insulin treatment on the hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. Diabetes 2000; 49: 244-52
114. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in the control of body weight and reproduction. Science 2000; 289: 2122-5
115. Makimura H, Mizuno TM, Roberts J, et al. Adrenalectomy reverses obese phenotype and restores hypothalamic melanocortin tone in leptin-deficient ob/ ob mice. Diabetes 2000; 49: 1917-23
116. Bray GA, Stern JS, Castonguay TW. Effect of adrenalectomy and high-fat diet on the fatty Zucker rat. Am J Physiol 1992; 262: E32-9
117. Castonguay TW, Dallman MF, Stern JS. Some metabolic and behavioral effects of adrenalectomy on obese Zucker rats. Am J Physiol 1986; 251: R923-33
118. Feldkircher KM, Mistry AM, Romsos DR. Adrenalectomy reverses pre-existing obesity in adult genetically obese (ob/ob) mice. Int J Obes 1996; 20: 232-5
119. Fletcher JM. Effects of adrenalectomy before weaning in the genetically obese. Br J Nutr 1986; 56: 141-51
120. Gosselin C, Cabanac M. Adrenalectomy lowers the bodyweight set-point in rats. Physiol Behav 1997; 62: 519-23
121. Ouerghi D, Rivest S, Richard D. Adrenalectomy attenuates the effect of chemical castration on energy balance in rats. J Nutr 1992; 122: 369-73
122. Romsos DR. Interactions between diet composition and adrenal secretions in energy balance in ob/ob mice. In: Romsos D, editor. Obesity: dietary factors and control. Basel: S. Karger, 1991: 39-44
123. York DA, Godbole V. Effect of adrenalectomy on obese 'fatty' rats. Horm Metab Res 1979; 11: 646
124. Solomon J, Mayer J. The effect of adrenalectomy on the development of the obese-hyperglycemic syndrome in ob/ob mice. Endocrinology 1973; 93: 510-3
125. Deshaies Y, Dagnault A, Lalonde J, et al. Interaction of corticosterone and gonadal steroids on lipid deposition in the female rat. Am J Physiol 1997; 36: E355-62
126. Bjorntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus. Diabet Med 1999; 16: 373-83
127. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 1999; 96: 513-23
128. Funder JW. Corticosteroid receptors in the brain. In: Motta M. editor. Brain endocrinology. New York (NY): Raven, 1991: 133-51
129. De Kloet ER. Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 1991; 12: 95-164
130. Funder JW. Glucocorticoid receptors. J Steroid Biochem Mol Biol 1992; 43: 389-94
131. Devenport L, Knehans A, Sundstrom A, et al. Corticosterone's dual metabolic actions. Life Sci 1989; 45: 1389-96
132. Ur E, Grossman A, Despres JP. Obesity results as a consequence of glucocorticoid induced leptin resistance. Horm Metab Res 1996; 28: 744-7
133. Arvaniti K, Deshaies Y, Richard D. Effect of leptin on energy balance does not require the presence of intact adrenals. Am J Physiol 1998; 275: R105-11
134. Bluher M, Windgassen M, Paschke R. Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma. Diabetes Care 2000; 23: 1591-2
135. Chavez M, Seeley RJ, Green PK, et al. Adrenalectomy increases sensitivity to central insulin. Physiol Behav 1997; 62: 631-4
136. Tschop M, Flora DB, Mayer JP, et al. Hypophysectomy prevents ghrelin-induced adiposity and increases gastric ghrelin secretion in rats. Obes Res 2002; 10: 991-9
137. Akana SF, Strack AM, Hanson ES, et al. Regulation of activity in the hypothalamo-pituitary-adrenal axis is integral to a larger hypothalamic system that determines caloric flow. Endocrinology 1994; 135: 1125-34
138. Kiss A, Jezova D, Aguilera G. Activity of the hypothalamic-pituitary- adrenal axis and sympathoadrenal system during food and water deprivation in the rat. Brain Res 1994; 663: 84-92
139. Woodward CJH, Hervey GR, Oakey RE, et al. The effects of fasting on plasma corticosterone kinetics in rats. Br J Nutr 1991 ; 66: 117-27
140. Sawchenko PE, Li HY, Ericsson A. Circuits and mechanisms governing hypothalamic responses to stress: a tale of two paradigms. Prog Brain Res 2000; 122: 61-78
141. Herman JP, Cullinan WE. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 1997; 20: 78-84
142. Ishizuka B, Quigley ME, Yen SS. Pituitary hormone release in response to food ingestion: evidence for neuroendocrine signals from gut to brain. J Clin Endocrinol Metab 1983; 57: 1111-6
143. Honma K, Honma S, Hirai T, et al. Food ingestion is more important to plasma Corticosterone dynamics than water intake in rats under restricted daily feeding. Physiol Behav 1986; 37: 791-5
144. Boivin A, Deshaies Y. Contribution of hyperinsulinemia to modulation of lipoprotein lipase activity in the obese Zucker rat. Metabolism 2000; 49: 134-40
145. Boivin A, Deshaies Y. Dietary rat models in which the development of hypertriglyceridemia and that of insulin resistance are dissociated. Metabolism 1995; 44: 1540-7
146. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142: 521-7
147. Han VK, Hynes MA, Jin C, et al. Cellular localization of proglucagon/glucagon-like peptide I messenger RNAs in rat brain. J Neurosci Res 1986; 16: 97-107
148. Goldstone AP, Morgan I, Mercer JG, et al. Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA. Biochem Biophys Res Commun 2000; 269: 331-5
149. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997; 138: 4445-55
150. Imeryuz N, Yegen BC, Bozkurt A, et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997; 273: G920-7
151. MacLusky NJ, Cook S, Scrocchi L, et al. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 2000; 141: 752-62
152. Hayashida T, Murakami K, Mogi K, et al. Ghrelin in domestic animals: distribution in stomach and its possible role. Dornest Anim Endocrinol 2001; 21: 17-24
153. Toshinai K, Mondal MS, Nakazato M, et al. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun 2001; 281: 1220-5
154. Tschop M, Wawara R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001; 24: RC19-21
155. Asakawa A, Inui A, Kaga T, et al. A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinology 2001; 74: 143-7
156. Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001; 86: 1169-74
157. Gura T. Obesity drug pipeline not so fat. Science 2003; 299: 849-52
158. Preti A. Axokine (Regeneron). Drugs 2003; 6: 696-701
159. Marsh DJ, Hollopeter G, Huszar D, et al. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet 1999; 21: 119-22
160. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003; 462: 125-32
161. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-53
162. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722-33
163. Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000; 16: 961-6